Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer By Ogkologos - November 24, 2025 190 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LUNAR study Source RELATED ARTICLESMORE FROM AUTHOR In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities MOST POPULAR New Cancer Model Shows Promise in Predicting If Treatment Will Shrink... July 28, 2022 For Early-Stage Cervical Cancer, Minimally Invasive Surgery Declining May 25, 2021 Stage IV Cancer Patient Clinging to Life Overseas While Family Raises... May 28, 2020 5-Yr-Old Cancer Survivor Used His Birthday To Collect Toys For Sick... October 15, 2019 Load more HOT NEWS EMA Adopts a Positive Opinion for Dabrafenib for the Treatment of... A Diagnosis of Advanced Lung Cancer Is Not a Death Sentence What to Know About Navigating Your Cancer Care During An Extreme... Opinion: ‘The idea that a tobacco company might profit off my...
